콘텐츠로 건너뛰기
Merck
모든 사진(1)

Key Documents

SML2227

Sigma-Aldrich

Emricasan

≥98% (HPLC), powder, pan-caspase inhibitor

동의어(들):

IDN-6556, N-[2-(1,1-dimethylethyl)phenyl]-2-oxoglycyl-N-[(1S)-1-(carboxymethyl)-2-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl]-L-Alaninamide, PF-03491390

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C26H27F4N3O7
CAS Number:
Molecular Weight:
569.50
MDL number:
UNSPSC 코드:
12352200
NACRES:
NA.77

product name

Emricasan, ≥98% (HPLC)

분석

≥98% (HPLC)

형태

powder

색상

white to beige

solubility

DMSO: 2 mg/mL, clear

배송 상태

wet ice

저장 온도

−20°C

SMILES string

CC(C)(C)C1=C(NC(C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(COC2=C(F)C(F)=CC(F)=C2F)=O)=O)=O)=O)C=CC=C1

InChI

1S/C26H27F4N3O7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17H,10-11H2,1-4H3,(H,31,38)(H,32,39)(H,33,37)(H,35,36)/t12-,17-/m0/s1

InChI key

SCVHJVCATBPIHN-SJCJKPOMSA-N

생화학적/생리학적 작용

Emricasan is an antiapoptotic pan-caspase inhibitor. It has been in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) with advanced fibrosis (scarring) and cirrhosis. Emricasan has also been shown to protect infected astrocytes from ZIKV-induced cell death.
Emricasan, formerly known as IDN-6556, in combination with birinapan is used to treat acute myeloid leukemia (AML). This small molecule irreversible inhibitor is under clinical investigation to reduce hepatic injury and liver fibrosis.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Carcinogenicity assessment of the pan-caspase inhibitor, emricasan, in Tg.rasH2 mice
Elbekai RH, et al.
Regulatory Toxicology and Pharmacology, 72, 169-178 (2015)
The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia
Brumatti G, et al.
Science Translational Medicine, 8, 339ra69-339ra69 (2016)
Haiyan Zhang et al.
Frontiers in cardiovascular medicine, 8, 685434-685434 (2021-08-03)
Dexrazoxane (DXZ) reduces cytotoxicity caused by Doxorubicin (DOX). However, the mechanism of DXZ in ferroptosis and cardiomyopathy remains unclear. This research, therefore, explores the role and mechanism of DXZ in DOX-induced ferroptosis and cardiomyopathy in rats. Kaplan-Meier survival analysis was

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.